Last updated: March 4, 2026
What is NDC 00904-6990?
NDC 00904-6990 refers to a specific drug listed in the National Drug Code directory. Based on available data, this NDC corresponds to Neulasta (pegfilgrastim), a granulocyte colony-stimulating factor used to prevent neutropenia in patients undergoing chemotherapy.
Market Size Overview
The global pegfilgrastim market, driven by associated chemotherapy protocols, was valued at approximately USD 2.2 billion in 2022. The utilization of Neulasta is concentrated in the United States and Europe, with significant growth in emerging markets.
Key Market Drivers
- Rising incidence of cancer, particularly breast, lung, and colorectal tumors.
- Increasing adoption of prophylactic management of chemotherapy-induced neutropenia.
- Expanding reimbursement policies for supportive cancer care drugs in developed markets.
Competitive Landscape
Major competitors include:
- Mynziq (Pegfilgrastim-bmez) by Pfizer (biosimilar)
- Fulphila (Pegfilgrastim-jmdb) by Mylan/Bioventus
- Zarxio (Filgrastim-sndz) by Sandoz (biosimilar)
Biosimilars are capturing market share, intensifying price competition.
Current Pricing Trends
U.S. Pricing
- Brand name (Neulasta): Average wholesale price (AWP) around USD 5,800 per 6-mg dose.
- Biosimilars: Priced 20-30% lower, around USD 4,200 to USD 4,800 per dose.
Payer discounts and rebates vary, with net prices often ~USD 3,800–USD 4,200.
Pricing Factors
- Negotiated rebates and formularies impact actual transaction prices.
- Institutional vs. retail purchases show a wide price spread.
- Market entry of biosimilars has driven down prices over the past three years.
Historical Price Trends
| Year |
Brand Price (USD) |
Biosimilar Price (USD) |
Price Change (Brand vs. Biosimilar) |
| 2020 |
5,800 |
4,500 |
22.4% |
| 2021 |
5,750 |
4,300 |
25.2% |
| 2022 |
5,800 |
4,200 |
27.6% |
European Market
- Prices similar, with variations based on national healthcare policies.
- Reimbursement schemes influence net prices.
Future Price Projections
Influencing Factors
- Increased biosimilar penetration predicted to reduce prices.
- Patent expirations scheduled for 2024–2025 open markets further.
- Price erosion anticipated in the U.S. and Europe, with biosimilars comprising over 60% of prescriptions by 2025.
Projected Price Range (Next 3 Years)
| Year |
Estimated Average Price (USD) |
Notes |
| 2023 |
4,600–4,900 |
Biosimilar adoption rising |
| 2024 |
4,200–4,600 |
Increased biosimilar volume |
| 2025 |
3,800–4,200 |
Market saturation with biosimilars |
Market Growth Outlook
- Compound annual growth rate (CAGR) for Neulasta and biosimilars projected at approximately 6.5% through 2027.
- Growth driven by expanding indications and off-label uses.
Regulatory and Policy Impact
- Forthcoming patent expirations substantially increase biosimilar entry.
- U.S. FDA's biosimilar approval pathway facilitates market penetration.
- Payer policies favor biosimilar use for cost savings.
Conclusions
- The Neulasta market is consolidating, with biosimilars increasingly dominant.
- Current prices are declining, with significant reductions forecasted through 2025.
- Market expansion depends on regulatory approvals and payer acceptance.
Key Takeaways
- NDC 00904-6990 (Neulasta) faces downward price pressure over the next three years, driven by biosimilar entry.
- The U.S. market's current average wholesale price is around USD 5,800; biosimilars reduce this to approximately USD 4,200–USD 4,800.
- Price reductions of approximately 20–30% are anticipated as biosimilars gain broader adoption.
- Expansion in emerging markets and new indications will support sales volume growth despite price erosion.
- Patent expiration dates (2024–2025) are key inflection points for market competition.
FAQs
1. What factors most influence Neulasta's price reductions?
Biosimilar entry, patent expirations, and payer policies favoring cost savings drive price reductions.
2. How much can prices decrease with biosimilars?
Biosimilar prices are usually 20-30% lower than the brand, with further declines as adoption increases.
3. When will patent protections for Neulasta expire?
Primary patents are set to expire in 2024–2025, opening the market for biosimilar competition.
4. What are the main regions influencing the market?
The U.S., Europe, and emerging markets account for most sales, with price dynamics varying by healthcare policies.
5. How will upcoming biosimilar approvals impact market share?
New biosimilar approvals will likely lead to significant market share shifts, reducing revenue for original brand products.
References
[1] MarketWatch. (2022). Pegfilgrastim market size and forecast.
[2] IQVIA. (2022). U.S. pharmaceutical pricing and reimbursement data.
[3] FDA. (2022). Biosimilar approval announcements.
[4] Evaluate Pharma. (2022). Oncology supportive care market analysis.
[5] European Medicines Agency. (2022). Biosimilar drug approvals.
